Filing Details
- Accession Number:
- 0001209191-16-092226
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-01-19 19:00:34
- Reporting Period:
- 2016-01-15
- Filing Date:
- 2016-01-19
- Accepted Time:
- 2016-01-19 19:00:34
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1290149 | Pronai Therapeutics Inc | DNAI | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1578888 | Nicholas Glover | C/O Pronai Therapeutics, Inc. 2150 885 West Georgia St. Vancouver A1 V6C 3E8 | Ceo And President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-01-15 | 5,000 | $0.97 | 5,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2016-01-15 | 5,000 | $10.04 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2016-01-15 | 5,000 | $0.00 | 5,000 | $0.97 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
864,219 | 2024-07-13 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.29 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The option vests as to 25% of the total shares on July 14, 2015, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on July 14, 2018, subject to the reporting person's provision of service to the issuer on each vesting date. The option is immediately exercisable.